Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021

Daniel S Graciaa; Hans P Verkerke; Jeannette Guarner; Ana Maria Moldoveanu; Narayanaiah Cheedarla; Connie M Arthur; Cheryl L Maier; Andrew Neish; Sara C Auld; Angie Campbell; Neel R Gandhi; John D Roback; N Sarita Shah

doi:10.1017/ash.2022.298

Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January-March 2021

Antimicrob Steward Healthc Epidemiol. 2022 Sep 22;2(1):e159. doi: 10.1017/ash.2022.298. eCollection 2022.

Authors

Affiliations

¹ Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
² Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
³ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁴ Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
⁵ Departments of Epidemiology and Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia.

Abstract

We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January-March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination.

Abstract

Grants and funding